Welcome to our dedicated page for OKYO PHARMA news (Ticker: OKYO), a resource for investors and traders seeking the latest updates and insights on OKYO PHARMA stock.
OKYO Pharma Limited develops investigational ophthalmic therapies for neuropathic corneal pain and inflammatory eye diseases. The company’s lead candidate, urcosimod, formerly OK-101, is described as a lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor, with development centered on ocular pain and inflammation.
Recurring company updates cover urcosimod clinical data, patient-reported outcomes from a completed Phase 2 study in neuropathic corneal pain, FDA IND and Fast Track status for the NCP program, scientific advisory and ophthalmology-conference presentations, ordinary-share ownership disclosures, and purchases of Nasdaq-listed ordinary shares by company insiders.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) has announced the activation of its first clinical trial site in the U.S. for a phase 2 study of its ophthalmic solution, OK-101, aimed at treating dry eye disease. The trial is a multi-center, randomized, double-blinded, placebo-controlled study designed to evaluate the efficacy and safety of OK-101. The first patient visit is anticipated within two weeks. CEO Gary S. Jacob emphasized the company's commitment to advancing OK-101’s development, noting that dry eye disease affects approximately 700 million people globally. OK-101 is a novel long-acting drug candidate developed to alleviate inflammation and pain associated with dry eye conditions.
OKYO Pharma Ltd. (NASDAQ:OKYO) is advancing towards its first phase 2 trial of the drug OK-101, with plans to release efficacy data by year-end 2023. To facilitate this, the company announced a private stock placement aimed at raising $5.7 million through the issuance of over 12 million shares (American Depositary Shares and Ordinary Shares). Notably, senior management has opted to take shares as compensation for deferred wages, showcasing their confidence in the company’s future. The phase 2 trial, set to commence in Q2 2023, focuses on treating chronic dry eye disease, a significant market valued at over $5 billion in 2019. The company collaborates with contract research organizations for efficient research execution.